Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease
Huntington's disease (HD) is a hereditary neurodegenerative disorder for which biological indicators of disease progression, or disease stage, would be especially important for therapeutic trials. 24S-hydroxycholesterol (24OHC) is a brain-generated cholesterol metabolite which has been associat...
Saved in:
Published in | Brain (London, England : 1878) Vol. 131; no. 11; pp. 2851 - 2859 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Oxford
Oxford University Press
01.11.2008
Oxford Publishing Limited (England) |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Huntington's disease (HD) is a hereditary neurodegenerative disorder for which biological indicators of disease progression, or disease stage, would be especially important for therapeutic trials. 24S-hydroxycholesterol (24OHC) is a brain-generated cholesterol metabolite which has been associated with neurodegeneration, and alterations of cholesterol metabolism in murine HD models and patients’ tissues have been recently identified. On these grounds, and with the aim of identifying putative biomarkers in HD, we studied cholesterol metabolism through the analysis in vivo of plasma 24OHC and cholesterol in two independent cohorts of controls and patients of Italian and British origin. We analysed a total of 62 controls, 96 HD symptomatic patients at different disease stages (stage 1–3), and 33 HD gene-positive pre-manifest subjects [pre-manifest HD (pre-HD)]. Cholesterol and 24OHC plasma levels were comparable in both the British and Italian subjects, and were not influenced by fasting or post-meal status. Cholesterol levels did not show differences between controls, pre-HD subjects and HD patients. In contrast, the plasma levels of 24OHC were significantly higher in controls than in HD patients at all disease stages (P < 0.001). Interestingly, in pre-HD subjects plasma 24OHC concentrations were similar to those of controls, and thus significantly greater than those of HD patients at any disease stage (P < 0.001). As expected, significant differences in caudate volumes between stage 1–2 HD patients and pre-HD subjects, and pre-HD subjects and controls were found. The pre-HD cohort of subjects was heterogeneous as to 24OHC levels, since subjects closer to predicted development of motor signs of disease had lower 24OHC levels than those far from onset. Our data indicate that the brain-generated cholesterol metabolite 24OHC measured in plasma was significantly depleted in HD patients at any disease stage, and it could discriminate pre-manifest subjects from patients with overt motor disease. However, 24OHC levels failed to mark further disease progression in patients with manifest HD. Overall, we demonstrate that 24OHC levels parallel the large decrease in caudate volumes observed in gene-positive subjects from pre-manifest to HD stage 1, thus reflecting a critical phase characterized by neuronal loss. We conclude that that 24OHC levels complement MRI morphometry as a valuable tool to follow neurodegenerative changes in the early stages of Huntington disease. |
---|---|
AbstractList | Huntington's disease (HD) is a hereditary neurodegenerative disorder for which biological indicators of disease progression, or disease stage, would be especially important for therapeutic trials. 24S-hydroxycholesterol (24OHC) is a brain-generated cholesterol metabolite which has been associated with neurodegeneration, and alterations of cholesterol metabolism in murine HD models and patients' tissues have been recently identified. On these grounds, and with the aim of identifying putative biomarkers in HD, we studied cholesterol metabolism through the analysis in vivo of plasma 24OHC and cholesterol in two independent cohorts of controls and patients of Italian and British origin. We analysed a total of 62 controls, 96 HD symptomatic patients at different disease stages (stage 1-3), and 33 HD gene-positive pre-manifest subjects [pre-manifest HD (pre-HD)]. Cholesterol and 24OHC plasma levels were comparable in both the British and Italian subjects, and were not influenced by fasting or post-meal status. Cholesterol levels did not show differences between controls, pre-HD subjects and HD patients. In contrast, the plasma levels of 24OHC were significantly higher in controls than in HD patients at all disease stages (P < 0.001). Interestingly, in pre-HD subjects plasma 24OHC concentrations were similar to those of controls, and thus significantly greater than those of HD patients at any disease stage (P < 0.001). As expected, significant differences in caudate volumes between stage 1-2 HD patients and pre-HD subjects, and pre-HD subjects and controls were found. The pre-HD cohort of subjects was heterogeneous as to 24OHC levels, since subjects closer to predicted development of motor signs of disease had lower 24OHC levels than those far from onset. Our data indicate that the brain-generated cholesterol metabolite 24OHC measured in plasma was significantly depleted in HD patients at any disease stage, and it could discriminate pre-manifest subjects from patients with overt motor disease. However, 24OHC levels failed to mark further disease progression in patients with manifest HD. Overall, we demonstrate that 24OHC levels parallel the large decrease in caudate volumes observed in gene-positive subjects from pre-manifest to HD stage 1, thus reflecting a critical phase characterized by neuronal loss. We conclude that that 24OHC levels complement MRI morphometry as a valuable tool to follow neurodegenerative changes in the early stages of Huntington disease. Huntington's disease (HD) is a hereditary neurodegenerative disorder for which biological indicators of disease progression, or disease stage, would be especially important for therapeutic trials. 24S-hydroxycholesterol (24OHC) is a brain-generated cholesterol metabolite which has been associated with neurodegeneration, and alterations of cholesterol metabolism in murine HD models and patients' tissues have been recently identified. On these grounds, and with the aim of identifying putative biomarkers in HD, we studied cholesterol metabolism through the analysis in vivo of plasma 24OHC and cholesterol in two independent cohorts of controls and patients of Italian and British origin. We analysed a total of 62 controls, 96 HD symptomatic patients at different disease stages (stage 1-3), and 33 HD gene-positive pre-manifest subjects [pre-manifest HD (pre-HD)]. Cholesterol and 24OHC plasma levels were comparable in both the British and Italian subjects, and were not influenced by fasting or post-meal status. Cholesterol levels did not show differences between controls, pre-HD subjects and HD patients. In contrast, the plasma levels of 24OHC were significantly higher in controls than in HD patients at all disease stages (P < 0.001). Interestingly, in pre-HD subjects plasma 24OHC concentrations were similar to those of controls, and thus significantly greater than those of HD patients at any disease stage (P < 0.001). As expected, significant differences in caudate volumes between stage 1-2 HD patients and pre-HD subjects, and pre-HD subjects and controls were found. The pre-HD cohort of subjects was heterogeneous as to 24OHC levels, since subjects closer to predicted development of motor signs of disease had lower 24OHC levels than those far from onset. Our data indicate that the brain-generated cholesterol metabolite 24OHC measured in plasma was significantly depleted in HD patients at any disease stage, and it could discriminate pre-manifest subjects from patients with overt motor disease. However, 24OHC levels failed to mark further disease progression in patients with manifest HD. Overall, we demonstrate that 24OHC levels parallel the large decrease in caudate volumes observed in gene-positive subjects from pre-manifest to HD stage 1, thus reflecting a critical phase characterized by neuronal loss. We conclude that that 24OHC levels complement MRI morphometry as a valuable tool to follow neurodegenerative changes in the early stages of Huntington disease.Huntington's disease (HD) is a hereditary neurodegenerative disorder for which biological indicators of disease progression, or disease stage, would be especially important for therapeutic trials. 24S-hydroxycholesterol (24OHC) is a brain-generated cholesterol metabolite which has been associated with neurodegeneration, and alterations of cholesterol metabolism in murine HD models and patients' tissues have been recently identified. On these grounds, and with the aim of identifying putative biomarkers in HD, we studied cholesterol metabolism through the analysis in vivo of plasma 24OHC and cholesterol in two independent cohorts of controls and patients of Italian and British origin. We analysed a total of 62 controls, 96 HD symptomatic patients at different disease stages (stage 1-3), and 33 HD gene-positive pre-manifest subjects [pre-manifest HD (pre-HD)]. Cholesterol and 24OHC plasma levels were comparable in both the British and Italian subjects, and were not influenced by fasting or post-meal status. Cholesterol levels did not show differences between controls, pre-HD subjects and HD patients. In contrast, the plasma levels of 24OHC were significantly higher in controls than in HD patients at all disease stages (P < 0.001). Interestingly, in pre-HD subjects plasma 24OHC concentrations were similar to those of controls, and thus significantly greater than those of HD patients at any disease stage (P < 0.001). As expected, significant differences in caudate volumes between stage 1-2 HD patients and pre-HD subjects, and pre-HD subjects and controls were found. The pre-HD cohort of subjects was heterogeneous as to 24OHC levels, since subjects closer to predicted development of motor signs of disease had lower 24OHC levels than those far from onset. Our data indicate that the brain-generated cholesterol metabolite 24OHC measured in plasma was significantly depleted in HD patients at any disease stage, and it could discriminate pre-manifest subjects from patients with overt motor disease. However, 24OHC levels failed to mark further disease progression in patients with manifest HD. Overall, we demonstrate that 24OHC levels parallel the large decrease in caudate volumes observed in gene-positive subjects from pre-manifest to HD stage 1, thus reflecting a critical phase characterized by neuronal loss. We conclude that that 24OHC levels complement MRI morphometry as a valuable tool to follow neurodegenerative changes in the early stages of Huntington disease. |
Author | Cattaneo, Elena Henley, Susie M. D. Hobbs, Nicola Z. Leoni, Valerio Wild, Edward J. Mariotti, Caterina Mandelli, Maria Luisa Grisoli, Marina Björkhem, Ingemar Di Donato, Stefano Tabrizi, Sarah J. Valenza, Marta |
Author_xml | – sequence: 1 givenname: Valerio surname: Leoni fullname: Leoni, Valerio organization: Unit Biochemistry and Genetics, Fondazione-IRCCS Istituto Neurologico Carlo Besta, Milan, Italy, Department of Neurodegenerative Disease and Dementia Research Centre, Institute of Neurology, University College London, UK, Department of Pharmacological Sciences and Centre for Stem Cell Research, University of Milan, Unit of Neuroradiology, Fondazione-IRCCS Istituto Neurologico Carlo Besta, Department of Bioengineering, Politecnico di Milano, Milan, Italy and Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska University Hospital, Stockholm, Sweden – sequence: 2 givenname: Caterina surname: Mariotti fullname: Mariotti, Caterina organization: Unit Biochemistry and Genetics, Fondazione-IRCCS Istituto Neurologico Carlo Besta, Milan, Italy, Department of Neurodegenerative Disease and Dementia Research Centre, Institute of Neurology, University College London, UK, Department of Pharmacological Sciences and Centre for Stem Cell Research, University of Milan, Unit of Neuroradiology, Fondazione-IRCCS Istituto Neurologico Carlo Besta, Department of Bioengineering, Politecnico di Milano, Milan, Italy and Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska University Hospital, Stockholm, Sweden – sequence: 3 givenname: Sarah J. surname: Tabrizi fullname: Tabrizi, Sarah J. organization: Unit Biochemistry and Genetics, Fondazione-IRCCS Istituto Neurologico Carlo Besta, Milan, Italy, Department of Neurodegenerative Disease and Dementia Research Centre, Institute of Neurology, University College London, UK, Department of Pharmacological Sciences and Centre for Stem Cell Research, University of Milan, Unit of Neuroradiology, Fondazione-IRCCS Istituto Neurologico Carlo Besta, Department of Bioengineering, Politecnico di Milano, Milan, Italy and Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska University Hospital, Stockholm, Sweden – sequence: 4 givenname: Marta surname: Valenza fullname: Valenza, Marta organization: Unit Biochemistry and Genetics, Fondazione-IRCCS Istituto Neurologico Carlo Besta, Milan, Italy, Department of Neurodegenerative Disease and Dementia Research Centre, Institute of Neurology, University College London, UK, Department of Pharmacological Sciences and Centre for Stem Cell Research, University of Milan, Unit of Neuroradiology, Fondazione-IRCCS Istituto Neurologico Carlo Besta, Department of Bioengineering, Politecnico di Milano, Milan, Italy and Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska University Hospital, Stockholm, Sweden – sequence: 5 givenname: Edward J. surname: Wild fullname: Wild, Edward J. organization: Unit Biochemistry and Genetics, Fondazione-IRCCS Istituto Neurologico Carlo Besta, Milan, Italy, Department of Neurodegenerative Disease and Dementia Research Centre, Institute of Neurology, University College London, UK, Department of Pharmacological Sciences and Centre for Stem Cell Research, University of Milan, Unit of Neuroradiology, Fondazione-IRCCS Istituto Neurologico Carlo Besta, Department of Bioengineering, Politecnico di Milano, Milan, Italy and Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska University Hospital, Stockholm, Sweden – sequence: 6 givenname: Susie M. D. surname: Henley fullname: Henley, Susie M. D. organization: Unit Biochemistry and Genetics, Fondazione-IRCCS Istituto Neurologico Carlo Besta, Milan, Italy, Department of Neurodegenerative Disease and Dementia Research Centre, Institute of Neurology, University College London, UK, Department of Pharmacological Sciences and Centre for Stem Cell Research, University of Milan, Unit of Neuroradiology, Fondazione-IRCCS Istituto Neurologico Carlo Besta, Department of Bioengineering, Politecnico di Milano, Milan, Italy and Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska University Hospital, Stockholm, Sweden – sequence: 7 givenname: Nicola Z. surname: Hobbs fullname: Hobbs, Nicola Z. organization: Unit Biochemistry and Genetics, Fondazione-IRCCS Istituto Neurologico Carlo Besta, Milan, Italy, Department of Neurodegenerative Disease and Dementia Research Centre, Institute of Neurology, University College London, UK, Department of Pharmacological Sciences and Centre for Stem Cell Research, University of Milan, Unit of Neuroradiology, Fondazione-IRCCS Istituto Neurologico Carlo Besta, Department of Bioengineering, Politecnico di Milano, Milan, Italy and Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska University Hospital, Stockholm, Sweden – sequence: 8 givenname: Maria Luisa surname: Mandelli fullname: Mandelli, Maria Luisa organization: Unit Biochemistry and Genetics, Fondazione-IRCCS Istituto Neurologico Carlo Besta, Milan, Italy, Department of Neurodegenerative Disease and Dementia Research Centre, Institute of Neurology, University College London, UK, Department of Pharmacological Sciences and Centre for Stem Cell Research, University of Milan, Unit of Neuroradiology, Fondazione-IRCCS Istituto Neurologico Carlo Besta, Department of Bioengineering, Politecnico di Milano, Milan, Italy and Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska University Hospital, Stockholm, Sweden – sequence: 9 givenname: Marina surname: Grisoli fullname: Grisoli, Marina organization: Unit Biochemistry and Genetics, Fondazione-IRCCS Istituto Neurologico Carlo Besta, Milan, Italy, Department of Neurodegenerative Disease and Dementia Research Centre, Institute of Neurology, University College London, UK, Department of Pharmacological Sciences and Centre for Stem Cell Research, University of Milan, Unit of Neuroradiology, Fondazione-IRCCS Istituto Neurologico Carlo Besta, Department of Bioengineering, Politecnico di Milano, Milan, Italy and Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska University Hospital, Stockholm, Sweden – sequence: 10 givenname: Ingemar surname: Björkhem fullname: Björkhem, Ingemar organization: Unit Biochemistry and Genetics, Fondazione-IRCCS Istituto Neurologico Carlo Besta, Milan, Italy, Department of Neurodegenerative Disease and Dementia Research Centre, Institute of Neurology, University College London, UK, Department of Pharmacological Sciences and Centre for Stem Cell Research, University of Milan, Unit of Neuroradiology, Fondazione-IRCCS Istituto Neurologico Carlo Besta, Department of Bioengineering, Politecnico di Milano, Milan, Italy and Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska University Hospital, Stockholm, Sweden – sequence: 11 givenname: Elena surname: Cattaneo fullname: Cattaneo, Elena organization: Unit Biochemistry and Genetics, Fondazione-IRCCS Istituto Neurologico Carlo Besta, Milan, Italy, Department of Neurodegenerative Disease and Dementia Research Centre, Institute of Neurology, University College London, UK, Department of Pharmacological Sciences and Centre for Stem Cell Research, University of Milan, Unit of Neuroradiology, Fondazione-IRCCS Istituto Neurologico Carlo Besta, Department of Bioengineering, Politecnico di Milano, Milan, Italy and Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska University Hospital, Stockholm, Sweden – sequence: 12 givenname: Stefano surname: Di Donato fullname: Di Donato, Stefano organization: Unit Biochemistry and Genetics, Fondazione-IRCCS Istituto Neurologico Carlo Besta, Milan, Italy, Department of Neurodegenerative Disease and Dementia Research Centre, Institute of Neurology, University College London, UK, Department of Pharmacological Sciences and Centre for Stem Cell Research, University of Milan, Unit of Neuroradiology, Fondazione-IRCCS Istituto Neurologico Carlo Besta, Department of Bioengineering, Politecnico di Milano, Milan, Italy and Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska University Hospital, Stockholm, Sweden |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20829215$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/18772220$$D View this record in MEDLINE/PubMed http://kipublications.ki.se/Default.aspx?queryparsed=id:117814400$$DView record from Swedish Publication Index |
BookMark | eNqF0t1r1TAYB-AgE3c2vfNaiqC7sS5J89FejoPbGRxRNgUZQnhPmrpsbVKTlu3898a1nosh7CohefLxJr8DtOe8Mwi9JvgjwVVxvAlg3THcOUroM7QgTOCcEi720AJjLPKy4ngfHcR4gzFhBRUv0D4ppaSU4gX6-bWF2EFG2WV-va2Dv9_qa9-aOJjg2wxcnWkYaxhM9vniPLMu64PJO3C2SeZh3kBot9lqdIN1vwbvjmJW22ggmpfoeQNtNK_m9hB9P_30bbnK11_Ozpcn61xzWgy5MLxkpGwM8NKwRjJZ6brEmvMac1oLLAivK6EpCNOUG2xk2UAlNaVNQzmw4hDl077xzvTjRvXBdhC2yoNV89Bt6hnFBWWUJv9-8n3wv8dUh-ps1KZtwRk_RiUqyTEu2ZOQVKySglUJvn0Eb_wYXCo6Gc4KSaRM6M2Mxk1n6t01__1GAu9mAFFD2wRw2sado7ikVfra5OjkdPAxBtMobQcYrHdDCkOrCFZ_o6EeoqGmaKRFHx4t2p3_f340cT_2T8n59W0Kzf3OQrhVQhaSq9WPKyUvisvV1bJQ6-IPI2DYXg |
CODEN | BRAIAK |
CitedBy_id | crossref_primary_10_1007_s40618_014_0098_1 crossref_primary_10_1016_j_cca_2019_01_022 crossref_primary_10_1016_S1474_4422_11_70070_9 crossref_primary_10_1111_febs_15727 crossref_primary_10_3109_10715760903321804 crossref_primary_10_1016_j_bbalip_2014_12_018 crossref_primary_10_1007_s00018_012_1083_5 crossref_primary_10_1038_nm0309_253 crossref_primary_10_1111_j_1471_4159_2010_06912_x crossref_primary_10_3390_antibiotics12010122 crossref_primary_10_1148_radiol_10091742 crossref_primary_10_1111_bph_16235 crossref_primary_10_3390_metabo14070394 crossref_primary_10_1016_j_tins_2017_05_002 crossref_primary_10_1038_nrdp_2015_5 crossref_primary_10_1111_j_1749_6632_2009_04943_x crossref_primary_10_1002_jms_4827 crossref_primary_10_1038_s41537_020_00121_4 crossref_primary_10_15252_emmm_201505413 crossref_primary_10_1016_j_nbd_2021_105346 crossref_primary_10_1002_mds_28391 crossref_primary_10_1007_s11011_021_00844_y crossref_primary_10_3233_JHD_170273 crossref_primary_10_3390_ijms25094696 crossref_primary_10_1111_epi_17232 crossref_primary_10_2478_jtim_2023_0142 crossref_primary_10_3390_ijms241311001 crossref_primary_10_1073_pnas_1002924107 crossref_primary_10_3390_biomedicines10061432 crossref_primary_10_1002_mds_25835 crossref_primary_10_1016_j_phrs_2023_106823 crossref_primary_10_3233_JHD_150170 crossref_primary_10_1016_j_expneurol_2014_04_021 crossref_primary_10_3389_fnagi_2022_797220 crossref_primary_10_15252_emmm_202012519 crossref_primary_10_1111_nan_12286 crossref_primary_10_3389_fnagi_2021_696778 crossref_primary_10_1016_j_bbalip_2016_09_011 crossref_primary_10_1016_j_neulet_2011_03_025 crossref_primary_10_1016_j_talo_2023_100278 crossref_primary_10_1111_nyas_14977 crossref_primary_10_1038_nrneurol_2014_24 crossref_primary_10_1177_0891988710383573 crossref_primary_10_3389_fneur_2022_940118 crossref_primary_10_1038_nrneurol_2011_132 crossref_primary_10_1016_j_parkreldis_2023_105488 crossref_primary_10_1042_BST20180135 crossref_primary_10_1517_17530059_2012_701205 crossref_primary_10_1016_j_chemphyslip_2011_04_002 crossref_primary_10_1038_cdd_2014_162 crossref_primary_10_1016_S1474_4422_09_70178_4 crossref_primary_10_1146_annurev_pharmtox_010715_103233 crossref_primary_10_1021_acs_biochem_5b00900 crossref_primary_10_1016_j_jchromb_2009_05_017 crossref_primary_10_3389_fneur_2021_657973 crossref_primary_10_3233_JHD_240030 crossref_primary_10_1051_medsci_2019253 crossref_primary_10_1093_brain_awz174 crossref_primary_10_1016_j_nbd_2013_03_013 crossref_primary_10_3390_biology14020129 crossref_primary_10_1016_j_nbd_2016_11_013 crossref_primary_10_1007_s13311_019_00731_6 crossref_primary_10_1016_j_neulet_2009_06_073 crossref_primary_10_14802_jmd_24232 crossref_primary_10_1523_JNEUROSCI_0917_10_2010 crossref_primary_10_1080_14789450_2020_1847086 crossref_primary_10_3390_cells13060469 crossref_primary_10_1016_j_bbi_2014_09_011 crossref_primary_10_1016_j_expneurol_2009_05_012 crossref_primary_10_3233_JHD_220552 crossref_primary_10_1016_j_bcp_2013_03_015 crossref_primary_10_1016_j_jns_2016_02_018 crossref_primary_10_1111_jnc_15228 crossref_primary_10_1194_jlr_R006338 crossref_primary_10_1007_s12035_024_04672_w crossref_primary_10_1016_j_biochi_2012_09_025 crossref_primary_10_3390_ph16111513 crossref_primary_10_1002_lipd_12041 crossref_primary_10_1016_j_neurol_2012_07_003 crossref_primary_10_1016_j_fct_2018_05_059 crossref_primary_10_1152_physrev_00041_2009 crossref_primary_10_1186_s13578_023_01053_z crossref_primary_10_1371_journal_pone_0070019 crossref_primary_10_1002_jcp_25488 crossref_primary_10_1016_j_bbrc_2014_01_188 crossref_primary_10_1186_s12868_014_0137_z crossref_primary_10_1016_j_celrep_2022_111953 crossref_primary_10_3390_pharmaceutics13111897 crossref_primary_10_1016_j_jconrel_2020_12_051 crossref_primary_10_1371_journal_pone_0146480 crossref_primary_10_1007_s12010_021_03523_x crossref_primary_10_1186_s13023_017_0742_x crossref_primary_10_3389_fnsyn_2021_618391 crossref_primary_10_1038_s41598_020_76973_8 crossref_primary_10_1016_j_ymgme_2011_12_005 crossref_primary_10_1038_s41582_023_00864_5 crossref_primary_10_1016_j_tins_2011_06_005 crossref_primary_10_1093_brain_awv384 crossref_primary_10_1194_jlr_D058487 crossref_primary_10_1002_mds_28089 crossref_primary_10_1007_s00415_023_11572_x crossref_primary_10_2217_fnl_11_38 |
Cites_doi | 10.1016/S0140-6736(07)60111-1 10.1038/nrn1474 10.1212/WNL.54.2.452 10.1097/00005072-199805000-00001 10.1212/WNL.44.8.1533 10.1006/nimg.2001.0978 10.1016/0092-8674(93)90585-E 10.1161/01.ATV.0000120374.59826.1b 10.1021/pr0700753 10.1002/ana.20121 10.1006/abio.1995.1110 10.1074/jbc.M303415200 10.1073/pnas.96.13.7238 10.1007/s00018-003-3018-7 10.1212/01.WNL.0000065888.88988.6E 10.1073/pnas.93.18.9799 10.1523/JNEUROSCI.3355-05.2005 10.1194/jlr.R400004-JLR200 10.1111/j.1600-0404.2006.00684.x 10.1016/j.nbd.2007.07.004 10.1016/S0304-3940(02)00887-X 10.1212/01.WNL.0000132965.14653.D1 10.1016/j.brainresbull.2006.10.028 10.1016/S1474-4422(04)00964-0 10.1212/01.wnl.0000174432.87383.87 10.1093/hmg/ddm170 10.1111/j.1365-2796.2006.01725.x 10.1093/clinchem/34.12.2456 10.1002/mds.870110204 10.1038/nrn1806 10.1016/j.cell.2006.04.026 |
ContentType | Journal Article |
Copyright | The Author (2008). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org 2008 2008 INIST-CNRS The Author (2008). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org |
Copyright_xml | – notice: The Author (2008). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org 2008 – notice: 2008 INIST-CNRS – notice: The Author (2008). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org |
DBID | BSCLL AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7QP 7QR 7TK 8FD FR3 K9. NAPCQ P64 7X8 ADTPV AOWAS |
DOI | 10.1093/brain/awn212 |
DatabaseName | Istex CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Calcium & Calcified Tissue Abstracts Chemoreception Abstracts Neurosciences Abstracts Technology Research Database Engineering Research Database ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Biotechnology and BioEngineering Abstracts MEDLINE - Academic SwePub SwePub Articles |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Nursing & Allied Health Premium Technology Research Database ProQuest Health & Medical Complete (Alumni) Chemoreception Abstracts Engineering Research Database Calcium & Calcified Tissue Abstracts Neurosciences Abstracts Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
DatabaseTitleList | MEDLINE Neurosciences Abstracts Nursing & Allied Health Premium MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1460-2156 |
EndPage | 2859 |
ExternalDocumentID | oai_swepub_ki_se_562422 1590062631 18772220 20829215 10_1093_brain_awn212 10.1093/brain/awn212 ark_67375_HXZ_7R3SHZC3_L |
Genre | Research Support, Non-U.S. Gov't Multicenter Study Journal Article |
GrantInformation_xml | – fundername: Telethon grantid: GGP06250 – fundername: Department of Health – fundername: Medical Research Council |
GroupedDBID | --- -E4 -~X .2P .55 .GJ .I3 .XZ .ZR 0R~ 1CY 1TH 23N 2WC 354 3O- 4.4 41~ 482 48X 53G 5GY 5RE 5VS 5WA 5WD 6PF 70D AABZA AACZT AAGKA AAIMJ AAJKP AAJQQ AAMDB AAMVS AAOGV AAPGJ AAPNW AAPQZ AAPXW AAQQT AARHZ AAUAY AAUQX AAVAP AAVLN AAWDT AAWTL AAYJJ ABDFA ABDPE ABEJV ABEUO ABGNP ABIME ABIVO ABIXL ABJNI ABKDP ABLJU ABMNT ABNGD ABNHQ ABNKS ABPIB ABPQP ABPTD ABQLI ABQNK ABSMQ ABVGC ABWST ABXVV ABXZS ABZBJ ABZEO ACBNA ACFRR ACGFS ACIWK ACPQN ACPRK ACUFI ACUKT ACUTJ ACUTO ACVCV ACYHN ACZBC ADBBV ADEYI ADEZT ADGKP ADGZP ADHKW ADHZD ADIPN ADMTO ADNBA ADOCK ADQBN ADRTK ADVEK ADYVW ADZXQ AEGPL AEHUL AEJOX AEKPW AEKSI AELWJ AEMDU AEMQT AENEX AENZO AEPUE AETBJ AEWNT AFFNX AFFQV AFFZL AFGWE AFIYH AFOFC AFSHK AFXAL AFYAG AGINJ AGKEF AGKRT AGMDO AGORE AGQPQ AGQXC AGSYK AGUTN AHGBF AHMBA AHMMS AHXPO AI. AIJHB AJBYB AJDVS AJEEA AJNCP AKWXX ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX ANFBD APIBT APJGH APWMN AQDSO AQKUS ARIXL ASAOO ASPBG ATDFG ATGXG ATTQO AVNTJ AVWKF AXUDD AYOIW AZFZN BAWUL BAYMD BCRHZ BEYMZ BHONS BQDIO BR6 BSCLL BSWAC BTRTY BVRKM BZKNY C1A C45 CAG CDBKE COF CS3 CXTWN CZ4 DAKXR DFGAJ DIK DILTD DU5 D~K E3Z EBS EE~ EIHJH EJD ELUNK EMOBN ENERS F5P F9B FECEO FEDTE FHSFR FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HVGLF HW0 HZ~ IOX J21 J5H JXSIZ KAQDR KBUDW KOP KQ8 KSI KSN L7B M-Z MBLQV MBTAY MHKGH ML0 MVM N4W N9A NGC NLBLG NOMLY NOYVH NTWIH NU- NVLIB O0~ O9- OAUYM OAWHX OBFPC OBOKY OCZFY ODMLO OHH OHT OJQWA OJZSN OK1 OPAEJ OVD OWPYF O~Y P2P PAFKI PB- PEELM PQQKQ Q1. Q5Y QBD R44 RD5 RIG RNI ROL ROX ROZ RUSNO RW1 RXO RZF RZO TCN TCURE TEORI TJX TLC TMA TR2 VH1 VVN W8F WH7 WOQ X7H X7M XJT XOL YAYTL YKOAZ YQJ YSK YXANX ZCG ZGI ZKB ZKX ZXP ~91 6.Y AASNB ABQTQ ABSAR ADJQC ADRIX AFXEN F20 G8K KC5 M49 AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7QP 7QR 7TK 8FD FR3 K9. NAPCQ P64 7X8 ADTPV AOWAS |
ID | FETCH-LOGICAL-c523t-6e58418fea58e4f7479cd80c55d052d60615d96c2a6ef8b0e78fa97c22ff25a43 |
ISSN | 0006-8950 1460-2156 |
IngestDate | Mon Sep 01 03:35:32 EDT 2025 Thu Jul 10 22:38:15 EDT 2025 Fri Jul 11 08:07:32 EDT 2025 Sun Jun 29 15:29:59 EDT 2025 Mon Jul 21 05:46:54 EDT 2025 Mon Jul 21 09:15:36 EDT 2025 Tue Jul 01 00:46:01 EDT 2025 Thu Apr 24 23:04:03 EDT 2025 Wed Aug 28 03:24:31 EDT 2024 Tue Aug 05 16:50:28 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 11 |
Keywords | oxysterol gas chromatography-mass spectrometry 24S-hydroxycholesterol biomarker caudate volume MRI Nervous system diseases Huntington disease Nuclear magnetic resonance imaging Genetic disease Cerebral disorder Gas chromatography Central nervous system disease Degenerative disease Mass spectrometry Extrapyramidal syndrome |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c523t-6e58418fea58e4f7479cd80c55d052d60615d96c2a6ef8b0e78fa97c22ff25a43 |
Notes | These authors contributed equally to this work. ArticleID:awn212 istex:70A25D2A8E19E438C04F336B9AAF31AB06F8BB3B ark:/67375/HXZ-7R3SHZC3-L ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
OpenAccessLink | https://academic.oup.com/brain/article-pdf/131/11/2851/16694672/awn212.pdf |
PMID | 18772220 |
PQID | 195437177 |
PQPubID | 35133 |
PageCount | 9 |
ParticipantIDs | swepub_primary_oai_swepub_ki_se_562422 proquest_miscellaneous_69750084 proquest_miscellaneous_19497649 proquest_journals_195437177 pubmed_primary_18772220 pascalfrancis_primary_20829215 crossref_citationtrail_10_1093_brain_awn212 crossref_primary_10_1093_brain_awn212 oup_primary_10_1093_brain_awn212 istex_primary_ark_67375_HXZ_7R3SHZC3_L |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2008-11-01 |
PublicationDateYYYYMMDD | 2008-11-01 |
PublicationDate_xml | – month: 11 year: 2008 text: 2008-11-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | Oxford |
PublicationPlace_xml | – name: Oxford – name: England |
PublicationTitle | Brain (London, England : 1878) |
PublicationTitleAlternate | Brain |
PublicationYear | 2008 |
Publisher | Oxford University Press Oxford Publishing Limited (England) |
Publisher_xml | – name: Oxford University Press – name: Oxford Publishing Limited (England) |
References | Aylward ( key 20170508031658_B2) 2004; 63 Björkhem ( key 20170508031658_B4) 2006; 185 Langbehn ( key 20170508031658_B16) 2004; 66 Lütjohann ( key 20170508031658_B20) 1996; 93 Whitwell ( key 20170508031658_B34) 2001; 22 Huntington Study ( key 20170508031658_B14) 1996; 11 Dalrymple ( key 20170508031658_B8) 2007; 6 Lund ( key 20170508031658_B18) 1999; 96 Lund ( key 20170508031658_B19) 2003; 278 Teunissen ( key 20170508031658_B27) 2005; 4 Valenza ( key 20170508031658_B30) 2007; 28 Leoni ( key 20170508031658_B17) 2002; 331 Gellera ( key 20170508031658_B11) 1996; 59 International Huntington Association (IHA) and the World Federation of Neurology (WFN) Research group on Huntington's Chorea ( key 20170508031658_B15) 1994; 44 Huntington's Disease Collaborative Research Group ( key 20170508031658_B13) 1993; 72 Walker ( key 20170508031658_B33) 2007; 369 Cohn ( key 20170508031658_B7) 1988; 34 Valenza ( key 20170508031658_B29) 2007; 16 Aylward ( key 20170508031658_B1) 2007; 72 Valenza ( key 20170508031658_B31) 2005; 25 Cattaneo ( key 20170508031658_B6) 2005; 6 Dzeletovic ( key 20170508031658_B10) 1995; 225 Graham ( key 20170508031658_B12) 2006; 125 Taroni ( key 20170508031658_B26) 2004; 5 Reading ( key 20170508031658_B23) 2004; 55 Tzourio-Mazoyer ( key 20170508031658_B28) 2002; 15 Björkhem ( key 20170508031658_B3) 2006; 260 Vonsattel ( key 20170508031658_B32) 1998; 57 Björkhem ( key 20170508031658_B5) 2004; 24 Rosas ( key 20170508031658_B25) 2003; 60 Rosas ( key 20170508031658_B24) 2005; 65 Dietschy ( key 20170508031658_B9) 2004; 45 Marder ( key 20170508031658_B21) 2000; 54 Pfriger ( key 20170508031658_B22) 2003; 60 |
References_xml | – volume: 369 start-page: 218 year: 2007 ident: key 20170508031658_B33 article-title: Huntington's disease publication-title: Lancet doi: 10.1016/S0140-6736(07)60111-1 – volume: 5 start-page: 641 year: 2004 ident: key 20170508031658_B26 article-title: Pathways to motor incoordination: the inherited ataxias publication-title: Nat Rev Neurosci doi: 10.1038/nrn1474 – volume: 54 start-page: 452 year: 2000 ident: key 20170508031658_B21 article-title: Rate of functional decline in Huntington's disease publication-title: Neurology doi: 10.1212/WNL.54.2.452 – volume: 57 start-page: 369 year: 1998 ident: key 20170508031658_B32 article-title: Huntington disease publication-title: J Neuropath Exp Neurol doi: 10.1097/00005072-199805000-00001 – volume: 44 start-page: 1533 year: 1994 ident: key 20170508031658_B15 article-title: Guidelines for the molecular genetics predictive test in Huntington's disease publication-title: Neurology doi: 10.1212/WNL.44.8.1533 – volume: 15 start-page: 273 year: 2002 ident: key 20170508031658_B28 article-title: Automated anatomical labelling of activations in spm using a macroscopic anatomical parcellation of the MNI MRI single subject brain publication-title: NeuroImage doi: 10.1006/nimg.2001.0978 – volume: 72 start-page: 971 year: 1993 ident: key 20170508031658_B13 article-title: A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes publication-title: Cell doi: 10.1016/0092-8674(93)90585-E – volume: 24 start-page: 806 year: 2004 ident: key 20170508031658_B5 article-title: Brain cholesterol: long secret life behind a barrier publication-title: Arterioscl Thromb Vasc Biol doi: 10.1161/01.ATV.0000120374.59826.1b – volume: 6 start-page: 2833 year: 2007 ident: key 20170508031658_B8 article-title: Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates publication-title: J Proteom Res doi: 10.1021/pr0700753 – volume: 66 start-page: 81 year: 2004 ident: key 20170508031658_B16 article-title: International Huntington's disease collaborative group. 2004. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length publication-title: Clin Genet – volume: 55 start-page: 879 year: 2004 ident: key 20170508031658_B23 article-title: Functional brain changes in presymptomatic Huntington's disease publication-title: Ann Neurol doi: 10.1002/ana.20121 – volume: 225 start-page: 73 year: 1995 ident: key 20170508031658_B10 article-title: Determination of cholesterol oxidation products in human plasma by isotope dilution-mass spectrometry publication-title: Anal Biochem doi: 10.1006/abio.1995.1110 – volume: 278 start-page: 22980 year: 2003 ident: key 20170508031658_B19 article-title: Knockout of the cholesterol-24-hydroxylase gene in mice reveals a brain-specific mechanism of cholesterol turnover publication-title: J Biol Chem doi: 10.1074/jbc.M303415200 – volume: 96 start-page: 7238 year: 1999 ident: key 20170508031658_B18 article-title: cDNA cloning of cholesterol 24-hydroxylase, a mediator of the cholesterol homeostasis in the brain publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.96.13.7238 – volume: 60 start-page: 1158 year: 2003 ident: key 20170508031658_B22 article-title: Cholesterol homeostasis and function in neurons of the central nervous system publication-title: Cell Mol Life Sci doi: 10.1007/s00018-003-3018-7 – volume: 60 start-page: 1615 year: 2003 ident: key 20170508031658_B25 article-title: Evidence for a more widespread cerebral pathology in early HD publication-title: Neurology doi: 10.1212/01.WNL.0000065888.88988.6E – volume: 93 start-page: 9799 year: 1996 ident: key 20170508031658_B20 article-title: Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.93.18.9799 – volume: 25 start-page: 9932 year: 2005 ident: key 20170508031658_B31 article-title: Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease publication-title: J Neurosci doi: 10.1523/JNEUROSCI.3355-05.2005 – volume: 45 start-page: 1375 year: 2004 ident: key 20170508031658_B9 article-title: Brain lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal publication-title: J Lipid Res doi: 10.1194/jlr.R400004-JLR200 – volume: 185 start-page: 43 year: 2006 ident: key 20170508031658_B4 article-title: Oxysterols and Alzheimer's disease publication-title: Acta Neurol Scand Suppl doi: 10.1111/j.1600-0404.2006.00684.x – volume: 28 start-page: 133 year: 2007 ident: key 20170508031658_B30 article-title: Progressive dysfunction of the cholesterol biosynthesis pathway in the R6/2 mouse model of Huntington's disease publication-title: Neurobiol Dis doi: 10.1016/j.nbd.2007.07.004 – volume: 331 start-page: 163 year: 2002 ident: key 20170508031658_B17 article-title: Changes in human plasma levels of 24S-hydroxycholesterol during progression of multiple sclerosis publication-title: Neurosci Lett doi: 10.1016/S0304-3940(02)00887-X – volume: 63 start-page: 66 year: 2004 ident: key 20170508031658_B2 article-title: Onset and rate of striatal atrophy in preclinical Huntington's disease publication-title: Neurology doi: 10.1212/01.WNL.0000132965.14653.D1 – volume: 72 start-page: 152 year: 2007 ident: key 20170508031658_B1 article-title: Change in MRI striatal volumes as a biomarker in preclinical Huntington disease publication-title: Brain Res Bull doi: 10.1016/j.brainresbull.2006.10.028 – volume: 4 start-page: 32 year: 2005 ident: key 20170508031658_B27 article-title: Biological markers in CSF and blood for axonal degeneration in multiple sclerosis publication-title: Lancet Neurol doi: 10.1016/S1474-4422(04)00964-0 – volume: 65 start-page: 745 year: 2005 ident: key 20170508031658_B24 article-title: Regional cortical thinning in preclinical Huntington disease and its relationships to cognition publication-title: Neurology doi: 10.1212/01.wnl.0000174432.87383.87 – volume: 59 start-page: 475 year: 1996 ident: key 20170508031658_B11 article-title: Errors in Huntington disease diagnostic test caused by trinucleotide deletion in the IT15 gene publication-title: Am J Hum Genet – volume: 16 start-page: 2187 year: 2007 ident: key 20170508031658_B29 article-title: Cholesterol biosynthetic pathway is impaired in YAC128 mice and is related to huntingtin expression publication-title: Hum Mol Genet doi: 10.1093/hmg/ddm170 – volume: 260 start-page: 493 year: 2006 ident: key 20170508031658_B3 article-title: Crossing the barrier: oxysterols as cholesterol transporters and metabolic modulators in the brain publication-title: J Intern Med doi: 10.1111/j.1365-2796.2006.01725.x – volume: 34 start-page: 2456 year: 1988 ident: key 20170508031658_B7 article-title: Lipoprotein cholesterol concentrations in the plasma of human subjects measured in the fed and fasted states publication-title: Clin Chem doi: 10.1093/clinchem/34.12.2456 – volume: 11 start-page: 136 year: 1996 ident: key 20170508031658_B14 article-title: The unified Huntington's disease rating scale: reliability and consistency publication-title: Mov Dis doi: 10.1002/mds.870110204 – volume: 6 start-page: 919 year: 2005 ident: key 20170508031658_B6 article-title: Normal huntingtin function: an alternative approach to Huntington's disease publication-title: Nat Rev Neurosci doi: 10.1038/nrn1806 – volume: 125 start-page: 1179 year: 2006 ident: key 20170508031658_B12 article-title: Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin publication-title: Cell doi: 10.1016/j.cell.2006.04.026 – volume: 22 start-page: 1483 year: 2001 ident: key 20170508031658_B34 article-title: Normalization of cerebral volumes by use of intracranial volume: implications for longitudinal quantitative MR imaging publication-title: Am J Neuroradiol |
SSID | ssj0014326 |
Score | 2.315527 |
Snippet | Huntington's disease (HD) is a hereditary neurodegenerative disorder for which biological indicators of disease progression, or disease stage, would be... |
SourceID | swepub proquest pubmed pascalfrancis crossref oup istex |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 2851 |
SubjectTerms | 24S-hydroxycholesterol Adult Biological and medical sciences biomarker Biomarkers - blood Brain Mapping - methods Caudate Nucleus - pathology caudate volume Cholesterol - blood Cohort Studies Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases Disease Progression Female gas chromatography-mass spectrometry Gas Chromatography-Mass Spectrometry - methods Humans Huntington Disease - blood Huntington Disease - pathology Hydroxycholesterols - blood Magnetic Resonance Imaging - methods Male Medical sciences Middle Aged MRI Neurology oxysterol Prognosis Young Adult |
Title | Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease |
URI | https://api.istex.fr/ark:/67375/HXZ-7R3SHZC3-L/fulltext.pdf https://www.ncbi.nlm.nih.gov/pubmed/18772220 https://www.proquest.com/docview/195437177 https://www.proquest.com/docview/19497649 https://www.proquest.com/docview/69750084 http://kipublications.ki.se/Default.aspx?queryparsed=id:117814400 |
Volume | 131 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1tb9MwELbKJiEkhHinDEY-8PKhSpc6duJ8RIOpGxtCW4emaVLkOI6oBumUtgL6p_iL3Nlu2qBWA75EqX2x6txj--zcPUfIS1WwJNe58GF1wZAczvyM8sJHbjFAiO4pZRxkP0b9U3Zwxs9arV9LXkvTSdZVs5VxJf-jVSgDvWKU7D9otm4UCuAe9AtX0DBc_0rHn8D0_SY7lJ34X37m6JCCk5nhPhhZCgAlp7il7xwd7xt_8Ur7SHhRgIyp14bfuG_zRRgzMB43PtrU3EdyWK5M_2HPFEQsls4UDvXIZIrqfIblp7KeXo6zAB1Ehi70ECMP61VhILNqOBvWp9Sdg-68ClspZ9KFFk1k46RCuJC9el-7OgKyMTtHvkgsEW1X2wmZRYEPZknUmLHdwuGg2VuegIXjr9Xzn8nKhcKSaGWVOX7Zk99L6ry5m-Tb60RvkE0K-xJMmfFu_0P92YqFJr9f3REXaQEt7Jjnd-zTDRtoE4fzj3l85e0rOYbBWdisKqu2PX9w2ho7aHCX3HEbGO-tReM90tLlfXLzyLloPCAXFpTealB6gBjPgdIDUHrD0lsGpak3oPQWoHwz9hwkH5LTvfeD3b7vUnj4itNw4kcaDNyeKLTkQrMC9q6JykWgOM8DTvMIDeo8iRSVkS5EFuhYFDKJFaVFQblk4SOyUY5K_YR4mK-Yq1gFQnKW53nGkoxrnqgI5KGiTTrzl5oqx2-PaVa-ptbPIkyNClKrgjZ5VUtfWV6XNXKvjX5qIVldoi9kzNP-2XkaH4cn_fPdMD1sEw8UeE1b2w3t1sIUA9wB5G2yNVd36qaZcYqUjGHci6GDL-paWAPww54s9WiKIgx2FSxZLwHviGPqjDZ5bFG0-KMCcUwD6KiFVV2DxPOu6BLudMoxlow-vb6jW-TWYvw_IxuTaqqfg-0-ybbNePkNJdjwfw |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Plasma+24S-hydroxycholesterol+and+caudate+MRI+in+pre-manifest+and+early+Huntington%27s+disease&rft.jtitle=Brain+%28London%2C+England+%3A+1878%29&rft.au=Leoni%2C+Valerio&rft.au=Mariotti%2C+Caterina&rft.au=Tabrizi%2C+Sarah+J.&rft.au=Valenza%2C+Marta&rft.date=2008-11-01&rft.pub=Oxford+University+Press&rft.issn=0006-8950&rft.eissn=1460-2156&rft.volume=131&rft.issue=11&rft.spage=2851&rft.epage=2859&rft_id=info:doi/10.1093%2Fbrain%2Fawn212&rft.externalDocID=10.1093%2Fbrain%2Fawn212 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0006-8950&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0006-8950&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0006-8950&client=summon |